Table 2.
Clinical profiles of T2DM patients treated with oral hypoglycemic agents (OHAs) in study 2
| SU | BG | α-GI | TZD | Glinide | DPP-4 inhibitor | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 228 | N = 325 | P-value | N = 203 | P-value | N = 140 | P-value | N = 70 | P-value | N = 307 | P-value | ||
| Age | 63.5 (62.4 ± 6.3) | 61 (60.8 ± 6.7) | 0.025 | 63 (61.3 ± 6.9) | 0.27 | 62 (60.5 ± 6.7) | 0.028 | 62 (61.1 ± 6.1) | 0.50 | 63 (61.6 ± 6.8) | 0.52 | |
| Male | 183 (80.3) | 206 (63.4) | - | 152 (74.9) | - | 101 (72.1) | - | 50 (71.4) | - | 216 (70.4) | - | |
| Anti-hypertensive agent and anti-dyslipidemia agent | None | 24 (10.5) | 49 (15.1) | - | 21 (10.3) | - | 20 (14.3) | - | 11 (15.7) | - | 34 (11.1) | - |
| Both of them | 109 (47.8) | 141 (43.4) | - | 126 (62.1) | - | 67 (47.9) | - | 30 (42.9) | - | 166 (54.1) | - | |
| One of them | 95 (41.7) | 135 (41.5) | - | 56 (27.6) | - | 53 (37.9) | - | 29 (41.4) | - | 107 (34.9) | - | |
| HbA1c (NGSP %) | 7.3 (7.6 ± 1.5) | 6.9 (7.1 ± 1.1) | <0.001 | 6.6 (6.7 ± 1.0) | <0.001 | 6.5 (6.8 ± 1.2) | <0.001 | 6.9 (6.9 ± 0.9) | <0.001 | 7.3 (7.6 ± 1.3) | 0.97 | |
| Minimum | 4.7 | 5.4 | 4.9 | 5.1 | 4.8 | 5.1 | ||||||
| Maximum | 14.1 | 14.4 | 11.4 | 11.8 | 9.4 | 13.7 | ||||||
| <6.5% | 44 (19.3) | 78 (24.0) | 87 (42.9) | 62 (44.3) | 21 (30.0) | 29 (9.4) | ||||||
| - | - | - | - | - | ||||||||
| 6.5 % ≤ | 184 (80.7) | 24.7 (76.0) | 116 (57.1) | 78 (55.7) | 49 (70.0) | 278 (90.6) | ||||||
| Duration of administration of baseline drug (days) | 616 (477 ± 279) | 730 (540 ± 261) | 0.022 | 700 (510 ± 263) | 0.56 | 596.5 (499 ± 251) | 0.90 | 524.5 (485 ± 251) | 1.00 | 302 (330 ± 245) | <0.001 | |
Data are n(%) or median (mean ± standard deviation). P-value: Dunnett’s test for SU